Trial Profile

A Phase 2/3 Single-Arm, Open-label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Obeldesivir in Pediatric Participants With COVID-19

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obeldesivir (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacokinetics
Sponsors Gilead Sciences

Most Recent Events

28 Mar 2024 Status changed from recruiting to discontinued.
13 Dec 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Nov 2023 to 1 Jan 2024.
13 Dec 2023 Planned initiation date changed from 1 Nov 2023 to 1 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com